AIMS: microRNA-122 (miR-122) is a hepatotoxicity biomarker with utility in the management of paracetamol overdose and in drug development. Renal dysfunction and haemodialysis have been associated with a reduction in circulating microRNA. The objective of this study was to determine their effect on miR-122. METHODS: Blood samples were collected from 17 patients with end-stage renal disease (ESRD) on haemodialysis, 22 healthy controls, 30 patients with chronic kidney disease (CKD) and 15 patients post-kidney transplantation. All had normal standard liver function tests. Samples from ESRD patients were collected immediately pre- and post-haemodialysis. Serum alanine transaminase activity (ALT), miR-122 and miR-885 (liver enriched) were compared. RESULTS: Circulating miR-122 was substantially reduced in ESRD patients pre-haemodialysis compared with the other groups (19.0-fold lower than healthy controls; 21.7-fold lower than CKD). Haemodialysis increased miR-122 from a median value of 6.7 × 103 (2.3 × 103 -1.4 × 104 ) to 1.6 × 104 (5.4 × 103 -3.2 × 104 ) copies ml-1 . The increase in miR-122 did not correlate with dialysis adequacy. miR-122 was reduced in the argonaute 2 bound fraction pre-haemodialysis; this fraction was increased post-dialysis. There was no change in miR-122 associated with extracellular vesicles. miR-885 was also reduced in ESRD patients (4-fold compared to healthy subjects) and increased by haemodialysis. CONCLUSION: miR-122 is substantially lower in ESRD compared to healthy controls, patients with CKD and transplanted patients. Haemodialysis increases the concentration of miR-122. These data need to be considered when interpreting liver injury using miR-122 in patients with ESRD on dialysis, and specific reference ranges that define normal in this setting may need to be developed.
AIMS: microRNA-122 (miR-122) is a hepatotoxicity biomarker with utility in the management of paracetamol overdose and in drug development. Renal dysfunction and haemodialysis have been associated with a reduction in circulating microRNA. The objective of this study was to determine their effect on miR-122. METHODS: Blood samples were collected from 17 patients with end-stage renal disease (ESRD) on haemodialysis, 22 healthy controls, 30 patients with chronic kidney disease (CKD) and 15 patients post-kidney transplantation. All had normal standard liver function tests. Samples from ESRD patients were collected immediately pre- and post-haemodialysis. Serum alanine transaminase activity (ALT), miR-122 and miR-885 (liver enriched) were compared. RESULTS: Circulating miR-122 was substantially reduced in ESRD patients pre-haemodialysis compared with the other groups (19.0-fold lower than healthy controls; 21.7-fold lower than CKD). Haemodialysis increased miR-122 from a median value of 6.7 × 103 (2.3 × 103 -1.4 × 104 ) to 1.6 × 104 (5.4 × 103 -3.2 × 104 ) copies ml-1 . The increase in miR-122 did not correlate with dialysis adequacy. miR-122 was reduced in the argonaute 2 bound fraction pre-haemodialysis; this fraction was increased post-dialysis. There was no change in miR-122 associated with extracellular vesicles. miR-885 was also reduced in ESRD patients (4-fold compared to healthy subjects) and increased by haemodialysis. CONCLUSION: miR-122 is substantially lower in ESRD compared to healthy controls, patients with CKD and transplanted patients. Haemodialysis increases the concentration of miR-122. These data need to be considered when interpreting liver injury using miR-122 in patients with ESRD on dialysis, and specific reference ranges that define normal in this setting may need to be developed.
Authors: Pajaree Lilitkarntakul; Neeraj Dhaun; Vanessa Melville; Scott Blackwell; Dinesh K Talwar; Barbara Liebman; Takae Asai; Jennifer Pollock; Jane Goddard; David J Webb Journal: Atherosclerosis Date: 2011-03-03 Impact factor: 5.162
Authors: Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley Journal: Nat Cell Biol Date: 2011-03-20 Impact factor: 28.824
Authors: Filippo Martino; Johan Lorenzen; Julius Schmidt; Mascha Schmidt; Michael Broll; Yvonne Görzig; Jan T Kielstein; Thomas Thum Journal: PLoS One Date: 2012-06-08 Impact factor: 3.240
Authors: Adriaan D B Vliegenthart; Philip Starkey Lewis; Carl S Tucker; Jorge Del Pozo; Sebastein Rider; Daniel J Antoine; Valérie Dubost; Magdalena Westphal; Pierre Moulin; Matthew A Bailey; Jonathan G Moggs; Chris E Goldring; B Kevin Park; James W Dear Journal: Zebrafish Date: 2014-03-13 Impact factor: 1.985
Authors: Wilna Oosthuyzen; Nicole E L Sime; Jessica R Ivy; Emma J Turtle; Jonathan M Street; John Pound; Louise E Bath; David J Webb; Christopher D Gregory; Matthew A Bailey; James W Dear Journal: J Physiol Date: 2013-09-23 Impact factor: 5.182
Authors: Yvan Devaux; Antonio Salgado-Somoza; Josef Dankiewicz; Adeline Boileau; Pascal Stammet; Anna Schritz; Lu Zhang; Mélanie Vausort; Patrik Gilje; David Erlinge; Christian Hassager; Matthew P Wise; Michael Kuiper; Hans Friberg; Niklas Nielsen Journal: Theranostics Date: 2017-06-25 Impact factor: 11.556
Authors: Laura Rivoli; A D Bastiaan Vliegenthart; Carmelita M J de Potter; Job J M H van Bragt; Nikolaos Tzoumas; Peter Gallacher; Tariq E Farrah; Neeraj Dhaun; James W Dear Journal: Br J Clin Pharmacol Date: 2016-10-21 Impact factor: 4.335